The Mechanisms of Action of Targeted Antibodies in Cancer Therapy

Understanding the mechanisms of action of targeted antibodies is crucial for appreciating their role in cancer therapy and their potential to improve patient outcomes. Targeted antibodies are engineered to recognize and bind specific antigens on cancer cells, leading to their destruction through various mechanisms, including direct inhibition of growth signals, induction of apoptosis, and recruitment of immune cells.

One of the primary mechanisms by which monoclonal antibodies (mAbs) work is by blocking critical signaling pathways that drive tumor growth. For example, trastuzumab targets the HER2 receptor, which is overexpressed in some breast cancers. By binding to HER2, trastuzumab blocks the receptor's ability to receive growth signals, thereby inhibiting cell proliferation and inducing cell death. Similarly, cetuximab targets the epidermal growth factor receptor (EGFR), blocking its signaling pathway and inhibiting the growth of colorectal and head and neck cancers.

Download Report:
https://www.kuickresearch.com/report-multispecific-antibodies-market-multispecific-antibody-market-clinical-trials-clinical-research

Another key mechanism of action is antibody-dependent cellular cytotoxicity (ADCC). When a targeted antibody binds to its antigen on a cancer cell, it can also engage immune effector cells, such as natural killer (NK) cells and macrophages, through its Fc region. This interaction triggers the release of cytotoxic molecules from the immune cells, leading to the destruction of the cancer cell. Rituximab, which targets CD20 on B-cells, is an example of an antibody that utilizes ADCC to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Complement-dependent cytotoxicity (CDC) is another mechanism by which targeted antibodies can kill cancer cells. Binding of the antibody to its antigen on the cancer cell surface can activate the complement cascade, a series of proteins that leads to the formation of membrane attack complexes (MAC) that lyse the cell membrane, resulting in cell death. This mechanism is also employed by rituximab in the treatment of B-cell malignancies.

Bispecific antibodies (BsAbs) enhance the immune response against cancer by engaging two different antigens simultaneously. For example, blinatumomab targets CD19 on B-cells and CD3 on T-cells. By bringing T-cells into close proximity with cancer cells, blinatumomab facilitates the direct killing of cancer cells by T-cells. This dual-targeting approach not only enhances the immune response but also addresses tumor heterogeneity, reducing the likelihood of resistance.

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy. ADCs are designed to deliver a potent cytotoxic drug directly to cancer cells. Once the ADC binds to its target antigen, it is internalized, and the cytotoxic drug is released inside the cell, leading to cell death. This targeted delivery minimizes systemic toxicity and enhances the anti-tumor effect. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer is an example of an ADC that utilizes this mechanism.

In addition to these direct mechanisms of action, targeted antibodies can also modulate the tumor microenvironment to enhance their therapeutic effects. For instance, some antibodies can inhibit angiogenesis, the process by which tumors develop new blood vessels to support their growth. Bevacizumab targets vascular endothelial growth factor (VEGF), blocking its signaling and reducing the blood supply to the tumor, thereby inhibiting tumor growth.

The combination of targeted antibodies with other therapeutic modalities, such as immune checkpoint inhibitors, can further enhance their mechanisms of action. Checkpoint inhibitors release the brakes on the immune system, allowing it to mount a stronger attack against cancer cells. When combined with targeted antibodies that increase the visibility of cancer cells to the immune system, this approach can provide a synergistic effect, improving treatment efficacy.

In conclusion, targeted antibodies employ various mechanisms of action to attack cancer cells, including blocking growth signals, inducing apoptosis, recruiting immune cells, and delivering cytotoxic drugs. Understanding these mechanisms is crucial for optimizing their use in cancer therapy and developing more effective and personalized treatment strategies.

KuicK Research
Delhi
India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.